MAPP: Summary for MAP Pharmaceuticals, Inc. - Yahoo! Singapore Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 5:41pm SGT - The Singapore stock market is closed.

To create a watchlist or portfolio of shares, Register

FINANCE HOME PAGE

INVESTING

FINANCE NEWS

MAP Pharmaceuticals, Inc. (MAPP)

At 5:00AM SGT: 14.98 USD 0.00 (0.00%)

MORE ON MAPP

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

MAP Pharmaceuticals, Inc. (NGM:MAPP) Delayed quote data

Last Trade:	14.98 USD
Trade Time:	5:00AM SGT
Change:	0.00 (0.00%)
Prev Close:	14.98
Open:	N/A
Bid:	12.50 x 100
Ask:	N/A
1y Target Est:	16.20

Day's Range:	N/A - N/A
52wk Range:	1.57 - 16.80
Volume:	0
Avg Vol (3m):	207,508
Market Cap:	366.92M
P/E (ttm):	N/A
EPS (ttm):	-0.82
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Use Y! Toolbar to track stocks

Add MAPP to Portfolio

Download Data

HEADLINES

•	MAP PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Fri, Feb 5)

•	Best Performing Stocks Year to Date
	at Seeking Alpha (Tue, Feb 2)

•	FDA Clears the Way for MAP Pharmaceuticals
	at Seeking Alpha (Sat, Jan 16)

•	Healthcare Stock Alert for MAP Pharmaceuticals Inc. issued by Beacon Equity
	GlobeNewswire (Wed, Jan 13)

•	Map Pharmaceuticals Shares on Good News for Migraine Drug
	at Fox Business (Tue, Jan 12)

•	[$$] MedCath Moves Up; Berry Slips 5.4%
	at The Wall Street Journal Online (Tue, Jan 12)

•	McMoRan Exploration, MAP Pharmaceuticals: Biggest Price Gainers (MMR, MAPP)
	at The Wall Street Journal Online (Tue, Jan 12)

•	Map Pharmaceuticals Inc and K Tron International Lead Small-Cap Percentage Gainers
	SmallCapInvestor.com (Tue, Jan 12)

•	Biotech Stocks: MAP, Inhibitex, Vivus lead drug stocks north
	at MarketWatch (Tue, Jan 12)

•	MAP Pharma says FDA doesn't need new Levadex study
	AP (Tue, Jan 12)

•	UPDATE - MAP says FDA waives second trial for migraine drug
	at Reuters (Tue, Jan 12)

•	Biotech Stocks: MAP and Vivus lead drug stocks north
	at MarketWatch (Mon, Jan 11)

More Headlines for MAPP...

ANALYST

EPS Est (next year) (Dec-09) :	-0.27
EPS Est (in 2 years) (Dec-10) :	-1.89
Avg Rec (current)*:	1.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•